Table Graph
      published meta-analysis   sensitivity analysis   studies

neutralizing antibody in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsSomersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.61[0.41; 0.92]Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202110%1,197NAnot evaluable deathsdetailed resultsSomersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.61[0.41; 0.92]Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202110%1,197NAnot evaluable death or ventilationdetailed resultsSomersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] 0.66[0.46; 0.94]Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202110%1,197NAnot evaluable hospital dischargedetailed resultsSomersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] 1.48[1.05; 2.09]Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202110%1,197NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-19 13:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 729,887,742,878,975,570,771,888,1141,690,880,1255 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons